CTLA4 and cancer: The success of anti-CTLA-4, anti-PD-L1 and anti-PD-1 antibodies in the treatment of various cancer types undoubtedly supports the idea of targeting inhibitory mechanisms that drive CTL dysfunctionality [16–18].